371 related articles for article (PubMed ID: 26439989)
1. Antitumoral activity of the mithralog EC-8042 in triple negative breast cancer linked to cell cycle arrest in G2.
Pandiella A; Morís F; Ocaña A; Núñez LE; Montero JC
Oncotarget; 2015 Oct; 6(32):32856-67. PubMed ID: 26439989
[TBL] [Abstract][Full Text] [Related]
2. A new oridonin analog suppresses triple-negative breast cancer cells and tumor growth via the induction of death receptor 5.
Wu J; Ding Y; Chen CH; Zhou Z; Ding C; Chen H; Zhou J; Chen C
Cancer Lett; 2016 Oct; 380(2):393-402. PubMed ID: 27387452
[TBL] [Abstract][Full Text] [Related]
3. The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus.
Vázquez R; Riveiro ME; Astorgues-Xerri L; Odore E; Rezai K; Erba E; Panini N; Rinaldi A; Kwee I; Beltrame L; Bekradda M; Cvitkovic E; Bertoni F; Frapolli R; D'Incalci M
Oncotarget; 2017 Jan; 8(5):7598-7613. PubMed ID: 27935867
[TBL] [Abstract][Full Text] [Related]
4. Zerumbone suppresses the motility and tumorigenecity of triple negative breast cancer cells via the inhibition of TGF-β1 signaling pathway.
Kim S; Lee J; Jeon M; Lee JE; Nam SJ
Oncotarget; 2016 Jan; 7(2):1544-58. PubMed ID: 26637807
[TBL] [Abstract][Full Text] [Related]
5. Antrodia salmonea induces G
Chang CT; Hseu YC; Thiyagarajan V; Huang HC; Hsu LS; Huang PJ; Liu JY; Liao JW; Yang HL
J Ethnopharmacol; 2017 Jan; 196():9-19. PubMed ID: 27986611
[TBL] [Abstract][Full Text] [Related]
6. Antitumor activity of the novel multi-kinase inhibitor EC-70124 in triple negative breast cancer.
Cuenca-López MD; Serrano-Heras G; Montero JC; Corrales-Sánchez V; Gomez-Juarez M; Gascón-Escribano MJ; Morales JC; Voisin V; Núñez LE; Morís F; Bader GD; Pandiella A; Ocaña A
Oncotarget; 2015 Sep; 6(29):27923-37. PubMed ID: 26314846
[TBL] [Abstract][Full Text] [Related]
7. Chk1 and Wee1 control genotoxic-stress induced G2-M arrest in melanoma cells.
Vera J; Raatz Y; Wolkenhauer O; Kottek T; Bhattacharya A; Simon JC; Kunz M
Cell Signal; 2015 May; 27(5):951-60. PubMed ID: 25683911
[TBL] [Abstract][Full Text] [Related]
8. Dual Inhibition of Key Proliferation Signaling Pathways in Triple-Negative Breast Cancer Cells by a Novel Derivative of Taiwanin A.
Kuo YH; Chiang EI; Chao CY; Rodriguez RL; Chou PY; Tsai SY; Pai MH; Tang FY
Mol Cancer Ther; 2017 Mar; 16(3):480-493. PubMed ID: 27956520
[TBL] [Abstract][Full Text] [Related]
9. Active kinase profiling, genetic and pharmacological data define mTOR as an important common target in triple-negative breast cancer.
Montero JC; Esparís-Ogando A; Re-Louhau MF; Seoane S; Abad M; Calero R; Ocaña A; Pandiella A
Oncogene; 2014 Jan; 33(2):148-56. PubMed ID: 23246963
[TBL] [Abstract][Full Text] [Related]
10. Targeting breast cancer stem cells in triple-negative breast cancer using a combination of LBH589 and salinomycin.
Kai M; Kanaya N; Wu SV; Mendez C; Nguyen D; Luu T; Chen S
Breast Cancer Res Treat; 2015 Jun; 151(2):281-94. PubMed ID: 25904215
[TBL] [Abstract][Full Text] [Related]
11. Granzyme B-based cytolytic fusion protein targeting EpCAM specifically kills triple negative breast cancer cells in vitro and inhibits tumor growth in a subcutaneous mouse tumor model.
Amoury M; Kolberg K; Pham AT; Hristodorov D; Mladenov R; Di Fiore S; Helfrich W; Kiessling F; Fischer R; Pardo A; Thepen T; Hussain AF; Nachreiner T; Barth S
Cancer Lett; 2016 Mar; 372(2):201-9. PubMed ID: 26806809
[TBL] [Abstract][Full Text] [Related]
12. BCL-XL blockage in TNBC models confers vulnerability to inhibition of specific cell cycle regulators.
Castellanet O; Ahmad F; Vinik Y; Mills GB; Habermann B; Borg JP; Lev S; Lamballe F; Maina F
Theranostics; 2021; 11(19):9180-9197. PubMed ID: 34646365
[TBL] [Abstract][Full Text] [Related]
13. Anti-cell growth and anti-cancer stem cell activities of the non-canonical hedgehog inhibitor GANT61 in triple-negative breast cancer cells.
Koike Y; Ohta Y; Saitoh W; Yamashita T; Kanomata N; Moriya T; Kurebayashi J
Breast Cancer; 2017 Sep; 24(5):683-693. PubMed ID: 28144905
[TBL] [Abstract][Full Text] [Related]
14. Targeting the cancer-associated fibroblasts as a treatment in triple-negative breast cancer.
Takai K; Le A; Weaver VM; Werb Z
Oncotarget; 2016 Dec; 7(50):82889-82901. PubMed ID: 27756881
[TBL] [Abstract][Full Text] [Related]
15. Mevastatin blockade of autolysosome maturation stimulates LBH589-induced cell death in triple-negative breast cancer cells.
Lin Z; Zhang Z; Jiang X; Kou X; Bao Y; Liu H; Sun F; Ling S; Qin N; Jiang L; Yang Y
Oncotarget; 2017 Mar; 8(11):17833-17848. PubMed ID: 28147319
[TBL] [Abstract][Full Text] [Related]
16. Dipalmitoylphosphatidic acid inhibits tumor growth in triple-negative breast cancer.
Zhang QQ; Chen J; Zhou DL; Duan YF; Qi CL; Li JC; He XD; Zhang M; Yang YX; Wang L
Int J Biol Sci; 2017; 13(4):471-479. PubMed ID: 28529455
[TBL] [Abstract][Full Text] [Related]
17. Induction of cell cycle arrest and inflammatory genes by combined treatment with epigenetic, differentiating, and chemotherapeutic agents in triple-negative breast cancer.
Merino VF; Cho S; Nguyen N; Sadik H; Narayan A; Talbot C; Cope L; Zhou XC; Zhang Z; Győrffy B; Sukumar S
Breast Cancer Res; 2018 Nov; 20(1):145. PubMed ID: 30486871
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of iNOS as a novel effective targeted therapy against triple-negative breast cancer.
Granados-Principal S; Liu Y; Guevara ML; Blanco E; Choi DS; Qian W; Patel T; Rodriguez AA; Cusimano J; Weiss HL; Zhao H; Landis MD; Dave B; Gross SS; Chang JC
Breast Cancer Res; 2015 Feb; 17(1):25. PubMed ID: 25849745
[TBL] [Abstract][Full Text] [Related]
19. Thymoquinone, a bioactive component of black caraway seeds, causes G1 phase cell cycle arrest and apoptosis in triple-negative breast cancer cells with mutant p53.
Sutton KM; Greenshields AL; Hoskin DW
Nutr Cancer; 2014; 66(3):408-18. PubMed ID: 24579801
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of the spindle assembly checkpoint kinase TTK enhances the efficacy of docetaxel in a triple-negative breast cancer model.
Maia AR; de Man J; Boon U; Janssen A; Song JY; Omerzu M; Sterrenburg JG; Prinsen MB; Willemsen-Seegers N; de Roos JA; van Doornmalen AM; Uitdehaag JC; Kops GJ; Jonkers J; Buijsman RC; Zaman GJ; Medema RH
Ann Oncol; 2015 Oct; 26(10):2180-92. PubMed ID: 26153498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
